Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions (Q39975486)

16 September 2017

Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions (English)

1 reference

16 September 2017

0 references

Uwe Muenster

1

1 reference

16 September 2017

Birgit Grieshop

series ordinal

2

1 reference

16 September 2017

Karsten Ickenroth

series ordinal

3

1 reference

16 September 2017

Mark Jean Gnoth

series ordinal

4

1 reference

16 September 2017

language of work or name

1 reference

4 June 2008

1 reference

16 September 2017

Pharmaceutical Research

1 reference

16 September 2017

25

1 reference

16 September 2017

10

1 reference

16 September 2017

2320-2326

1 reference

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

16 September 2017

1 reference

12 December 2020

Role of ABCG2/BCRP in biology and medicine

1 reference

12 December 2020

Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures

1 reference

12 December 2020

Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells

1 reference

12 December 2020

Identification of Residues in the Drug-binding Domain of Human P-glycoprotein

1 reference

12 December 2020

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

1 reference

12 December 2020

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

1 reference

12 December 2020

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

1 reference

12 December 2020

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

1 reference

12 December 2020

Rational use of in vitro P-glycoprotein assays in drug discovery

1 reference

12 December 2020

Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface

1 reference

12 December 2020

Drug transporters in pharmacokinetics

1 reference

12 December 2020

Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.

1 reference

12 December 2020

Structure of a bacterial multidrug ABC transporter

1 reference

12 December 2020

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

12 December 2020

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance

1 reference

12 December 2020

Transporters as a determinant of drug clearance and tissue distribution

1 reference

12 December 2020

Breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis

1 reference

12 December 2020

Projection structure of P-glycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains

1 reference

12 December 2020

Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state.

1 reference

12 December 2020

Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport

1 reference

12 December 2020

Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery

1 reference

12 December 2020

Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.

1 reference

12 December 2020

Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability

1 reference

12 December 2020

Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Reversal of P-glycoprotein-associated multidrug resistance by ivermectin

1 reference

12 December 2020

The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability

1 reference

12 December 2020

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

12 December 2020

Communication between multiple drug binding sites on P-glycoprotein

1 reference

12 December 2020

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

1 reference

12 December 2020

10.1007/S11095-008-9632-1

Identifiers

DOI

1 reference

16 September 2017

1 reference